DYN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Dyne Therapeutics is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Dyne Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Dyne Therapeutics's Risk Assessment falls into.
Dyne Therapeutics (NAS:DYN) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Dyne Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Dirk Kersten | director, 10 percent owner | C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC |
Joshua T Brumm | director, officer: See Remarks | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Jonathan Mcneill | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Oxana Beskrovnaya | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Richard William Scalzo | officer: See Remarks | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Wildon Farwell | officer: Chief Medical Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451 |
Susanna Gatti High | officer: Chief Operating Officer | 75 LORIMER ROAD, BELMONT MA 02141 |
Atlas Venture Associates Opportunity Ii, Lp | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Jason P Rhodes | director, 10 percent owner | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Llc | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Carlo Incerti | director | FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC |
Romesh Subramanian | 10 percent owner, officer: Chief Scientific Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Cureduchenne Ventures, Llc | 10 percent owner | 1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660 |
From GuruFocus
By GuruFocus Research • 06-15-2023
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 11-02-2022
By Marketwired • 11-07-2023
By Marketwired • 09-28-2023
By GuruFocus Research • 10-31-2023
By Value_Insider Value_Insider • 10-31-2022
By sperokesalga sperokesalga • 03-23-2023
By GuruFocus Research • 09-14-2023
By Stock market mentor Stock market mentor • 01-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.